ESMO 2023 | C-144-01: lifileucel in mucosal melanoma pretreated with ICIs

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from the Phase II C-144-01 trial (NCT02360579) of lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with mucosal melanoma pretreated with immune checkpoint inhibitors (ICIs). Lifileucel produced durable anti-tumor activity, potentially providing a novel treatment strategy for a group of patients with limited treatment options. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.